James Udelson, MD, discusses the Cycle-2-PEF trial, which ultimately supports the inverse dose-response hypothesis from companion trial Cycle-1-REF.
James Udelson, MD
Advertisement
James Udelson, MD, is the chief of the division of cardiology at Tufts Medical Center.
Articles by James Udelson, MD
James Udelson, MD, discusses the results of the Cycle-1-REF study, presented at HFSA 2026, that could support an inverse dose-response relationship with this PDE9 inhibitor.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations
2
Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD
3
Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism
4
ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
5